Introduction {#s1}
============

*Escherichia coli* is both a commensal and an opportunistic pathogen of the digestive tract of mammals. *E. coli* is also responsible for many extra-intestinal infections (ExPEC), such as those of the urinary tract (Pitout, [@B34]). Concomitantly, the spread of resistances to extended-spectrum cephalosporins (ESCs) used in human and veterinary medicine causes major therapeutic challenges worldwide (Naseer and Sundsfjord, [@B30]). Indeed, in *E. coli*, the vast dissemination of Extended-Spectrum β-Lactamases (ESBLs) is a concern, in particular due to the broad success of the CTX-M enzymes. ESBL genes are mostly plasmid-mediated and this obviously facilitates their dissemination amongst bacteria (Carattoli, [@B6]). In addition, plasmidic class C beta-lactamases (AmpCs), such as the CMY-2 enzyme, also confer resistance to those last-generations antibiotics and disseminate efficiently in *Enterobacteriaceae*. In certain countries, a significant prevalence of CMY-2 producers in animals has been reported (Mulvey et al., [@B29]).

Numerous *Enterobacteriaceae* naturally produce a chromosome-encoded AmpC cephalosporinase. In *E. coli*, this enzyme is usually expressed at very low levels, as a result of a weak promoter and a transcriptional attenuator preceeding the *ampC* gene. Nevertheless, constitutive over-expression of the chromosomal *ampC* gene was largely reported in clinical isolates. This was attributed to specific spontaneous mutations in the promoter (which creates close homologies with the *E. coli* perfect consensus sequence) or the attenuator (which destabilizes the mRNA hairpin structure) of the *ampC* gene. Consequently, both mechanisms confer resistance to narrow-spectrum cephalosporins. In human medicine, oxyminocephalosporins, such as cefepime and cefpirome, remain usually active against over-expressed AmpC-producing *Enterobacteriaceae*, thanks to their rapid penetration through the outer membrane and poor degradation by AmpC beta-lactamases.

More recently, nucleotides substitutions within the coding region of the *ampC* gene were shown to be responsible for an expanded hydrolysis spectrum of AmpC enzymes to oxyiminocephalosporins (Mammeri et al., [@B23], [@B25]). Amino acid deletions or insertions (Doi et al., [@B14]; Mammeri et al., [@B26]) of the cephalosporinase also broaden the hydrolysis spectrum. Those so-called Extended-Spectrum AmpC β-lactamases (ESACs) were not only reported in *E. coli*, but also in other *Enterobacteriaceae*, such as *Enterobacter cloacae* (Crichlow et al., [@B12]; Barnaud et al., [@B3]; Vakulenko and Golemi, [@B41]), *Enterobacter aerogenes* (Barnaud et al., [@B2]), *Citrobacter freundii* (Ahmed and Shimamoto, [@B1]) or *Serratia marcescens* (Matsumura et al., [@B27]; Raimondi et al., [@B35]; Mammeri et al., [@B24]; Hidri et al., [@B16]), and even in *Pseudomonas aeruginosa* and *Acinetobacter baumanii* (Rodriguez-Martinez et al., [@B37], [@B36]). ESACs were considered an emerging mechanism of resistance to beta-lactams and their prevalence was estimated around 0.2%, almost identical to that of plasmidic cephalosporinases (Mammeri et al., [@B21]). Among the modifications of the *ampC* gene in ESAC-producing *E. coli*, certain nucleotides substitutions were more frequently identified, such as the S287N replacement. Other replacements were found in the coding sequence of plasmid-borne AmpCs (Kim et al., [@B17]), which also contribute to the extension of their hydrolysis spectrum. Finally, ESAC *E. coli* producers were predominantly found to belong to the Clonal Complex (CC) 23 (Cremet et al., [@B11]), and this raises the question on the selection scheme of those isolates.

To date, ESACs were reported in human isolates only. The purpose of this study was thus to detect and characterize the very first ESAC producers in animals worldwide.

Materials and methods {#s2}
=====================

Bacterial isolates
------------------

A total of 6765 non-replicate *E. coli* isolates collected from cattle between February 2005 and December 2010 in France were included in this study. They were mostly recovered from fecal samples and from diseased animals (*n* = 6158), in particular from calves severely affected with gastro-enteritidis. Those isolates were recovered through the Resapath, the long-term surveillance network for antimicrobial resistance in pathogenic bacteria in France ([www.resapath.anses.fr](http://www.resapath.anses.fr)). An additional set of *E. coli* isolates (*n* = 607) collected from healthy French cattle (carriage) was also included. These latter isolates were recovered during a unique sampling program at slaughterhouse in 2006--2007. All isolates originated from various districts throughout the country and, when originating from the same district, came from different and widely distant farms. As the definition of AmpC over-producers may vary among studies (in particular with regard to resistance or not to expanded-spectrum cephalosporins in line with the strength of the *ampC* promoter), inclusion criteria for AmpC over-production were defined as follows, i.e., resistance to amoxicillin and amoxicillin-clavulanic acid, resistance to narrow-spectrum cephalosporins, reduced susceptibility to cefoxitin \[diameter \<22 mm, using the criteria of the Antibiogram Committee of the French Society for Microbiology (CA-SFM); ([www.sfm-microbiologie.fr](http://www.sfm-microbiologie.fr))\] and resistance to ceftazidime (MIC ≥6 μg/ml) with a negative double-disk synergy test. For presumptive ESAC production, a reduced susceptibility to cefepime (MIC ≥0.5 μg/ml) was further added as an inclusion criterion.

Antimicrobial susceptibility testing
------------------------------------

Resistance to beta-lactams and non-beta-lactams was determined by the disc diffusion method according to the guidelines of the CA-SFM. *E. coli* ATCC 25922 was used as the quality control strain. The inhibitory effect of cloxacillin on AmpC production was observed on plates supplemented with 200 mg/L cloxacillin (AES Chemunex, Bruz, France). MICs to cefoxitin, ceftazidime, cefotaxime, and cefepime were determined by *E*-test (BioMérieux, Marcy l\'Etoile, France) on all presumptive ESACs, and MICs to cefoxitin, ceftazidime, cefepime, and imipenem were also determined by *E*-test on the recombinant *E. coli* clones. As *E*-tests were not available for ceftiofur, MICs to ceftiofur were determined by broth dilution method on the recombinant *E. coli* clones.

Phylogroup analysis and molecular typing of *E. coli* isolates
--------------------------------------------------------------

All *E. coli* isolates with reduced susceptibility to cefepime were assigned to a phylogenetic group (A, B1, B2, or D) using the PCR described by Clermont et al. ([@B8]). Genetic relatedness of these isolates was determined by Pulse-Field Gel Electrophoresis (PFGE) after digestion with the *Bln*I restriction enzyme. Multi-Locus Sequence Typing was performed according to the scheme described on the *E. coli* MLST website (<http://mlst.ucc.ie/mlst/dbs/Ecoli>).

Characterization and sequence analysis of the β-lactamase and ampC genes
------------------------------------------------------------------------

The *bla*~SHV~, *bla*~TEM~, *bla*~OXA~, and *bla*~CTX−M~ genes were searched by PCR as previously described (Shibata et al., [@B38]; Dierikx et al., [@B13]). The plasmidic AmpC *bla*~CMY−2~ gene was sought using previously published primers (Mammeri et al., [@B22]). Chromosomal *ampC* promoter mutations were detected by PCR and sequencing of a 271 bp amplicon encompassing the −35 box, the −10 box and the attenuator (Caroff et al., [@B7]). The entire *ampC* gene of *E. coli* including its own promoter sequence was analyzed by PCR and sequencing using the Int-B2 and Int-H1 primers (Mammeri et al., [@B25]).

Cloning of the *ampC* genes
---------------------------

The coding region (without the promoter) of *ampC* genes from *E. coli* with a reduced susceptibility to cefepime was amplified with primers Int-B1 and Int-HN, as previously described (Mammeri et al., [@B25]). These 1120 bp products were cloned into pCR BluntII TOPO (Invitrogen) and the recombinant plasmids were transformed into *E. coli* strain TOP10. Transformants were selected on plates containing kanamycin (50 μg/ml) and ceftazidime (1 μg/ml). The orientation of the insert was confirmed by PCR with the SP6 and T7 primers in order to only keep transformants with the *ampC* gene under the transcriptional control of the *lacZ* promoter.

Results {#s3}
=======

Prevalence of presumptive ESAC producers
----------------------------------------

Amongst the 6765 *E. coli* isolates studied, a total of 80 isolates (1.18%) met the criteria of AmpC over-production, of which 71 were clinical *E. coli* isolates (diarrheic calves) and 9 from healthy animals (carriage). Of them, 28 *E. coli* isolates harbored an additional reduced susceptibility to cefepime (MICs ranging from 0.5 to 12 μg/ml) and were investigated as presumptive ESACs producers (Table [1](#T1){ref-type="table"}). MICs for ceftazidime for those 28 isolates ranged from 6 to 96 μg/ml, without a positive synergy test. Twenty-three presumptive ESACs producers (23/28, 82.1%) were from diseased cattle and 5 (5/28, 17.9%) were from healthy ones. None of the 28 *E. coli* had a plasmid-mediated *bla*~CMY~ gene, whereas 10 had a *bla*~TEM\ −1~ gene, 3 a *bla*~OXA−1~ gene, and 2 a *bla*~CTX−M−1~ gene. The 28 cattle were from different geographic origin in France, and *E. coli* were genetically unrelated (using PFGE, Table [1](#T1){ref-type="table"}). However, most of them (18/28, 64.2%, Table [1](#T1){ref-type="table"}) were of sequence type (ST) 88 belonging to the CC23. ST783 and ST1615 were also found four times each, respectively.

###### 

**Characteristics of the 28 *E. coli* strains presenting a reduced susceptibility to cefepime**.

![](fmicb-05-00053-i0001)

^a^ND, not determined.

^b^CAZ, ceftazidime; CTX, cefotaxime; FOX, cefoxitin; FEP, cefepime.

^c^ST, sequence type; CC, clonal complex.

^d^del, deletion, ins, insertion.

Mutations in the *ampC* promoter/attenuator and in the *ampC* gene
------------------------------------------------------------------

Compared with the *E. coli* ATCC 25922, sequencing of the *ampC* promoter revealed highly conserved mutations at position −88, −82, −42, −18, −1, and +58. The number of nucleotides between the novel −35 and −10 sequences was 17 bp in all isolates. Mutations in the *ampC* gene attenuator (from +17 to +37) were frequent, particularly at position +20, but also at +23 or +34 (Table [1](#T1){ref-type="table"}). Nucleotides deletion or insertion (at positions +1 or +33, respectively) were occasionally identified. Full sequencing of the *ampC* gene showed that amino acid substitutions of the AmpC beta-lactamase were mainly detected inside or near the H-10 helix (Figure [1](#F1){ref-type="fig"}) at positions 287 (*n* = 16; mostly S287N, but also S287C), 292 (*n* = 2, A292V) and 296 (*n* = 8; H296P), but also outside this hot spot at positions 89 (*n* = 1, A89T), 194 (*n* = 1, P194A), 215 (*n* = 4; A215V), 220 (*n* = 1; A220T), and 232 (*n* = 1, R232C) (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). The majority of the isolates presented one mutation in the coding sequence (*n* = 23), but three isolates presented two mutations and one isolate even presented four of them. Finally, one isolate which additionally harbored a CTX-M enzyme presented no mutation of the *ampC* gene compared the control.

![**Amino acids alignments of the ESAC β-lactamases** AmpC EC2 is a published narrow-spectrum cephalosporinase that was included as a reference strain. Point mutations are marked with a star. The two loops (Ω and R2) are highlighted in gray. Helix H-9, H-10, and H-11 are boxed.](fmicb-05-00053-g0001){#F1}

Characterization of the *ampC* recombinant *E. coli* clones
-----------------------------------------------------------

A subset of 7 *E. coli* isolates representative of the various amino acid substitutions found alone or in combination (A215V, A220T, S287N, S287C, A292V, H296P) and one control (15829, strain susceptible to cefepime) were chosen for cloning experiments (Table [2](#T2){ref-type="table"}). PCR products of 1120 bp corresponding to the *ampC* coding sequence without its promoter were cloned into pCR BluntII TOPO. The seven recombinant plasmids were successfully transformed into *E. coli* strain TOP10, giving rise to clones TF-15166, TF-19023, TF-15816, TF-18991, TF-25456, TF-16290, TF-20098, and TF-15829 (susceptible control). In all recombinant plasmids, the insert was proved to be under the transcriptional control of the *lacZ* promoter. MICs of beta-lactams determined for the recombinant clones showed that the S287N substitution had a greater impact on resistance than S287C, H296P, and A292V (Table [2](#T2){ref-type="table"}). TF-15166 and TF-19023 shared the same H296P mutation, but TF-15166 additionally harbored an A215V mutation that did not further increase the resistance to cefepime (MIC = 2 mg/L vs. MIC = 4 mg/L for TF-19023). The A215V had also weak impact on the susceptibility to cefepime when tested alone (TF-25456). Isolates 20098 displayed four different mutations (A89T, P194A, A220T, R232C), which do not increase resistance to cefepime (MIC = 0.19 mg/L) and were not found alone in the other tested isolates. TF-15829 (susceptible control) showed high MICs to ceftazidime (MIC = 24 mg/L) and cefoxitin (\>256 mg/L) but a similar MIC value to cefepime (MIC = 0.125 mg/L) that TF-25456 or TF-20098. No mutation in the coding sequence of the *ampC* gene was found in TF-15829 compared to the reference strain.

###### 

**Characteristics of the 7 *E. coli* transformants representative of the strains presenting a reduced susceptibility to cefepime**.

  **Isolate**                              **Date**   **MIC (mg/L) in transformants**   **Mutations in the *ampC* sequence**                         
  ---------------------------------------- ---------- --------------------------------- -------------------------------------- ------- ------- ----- ---------------------------
  **REDUCED SUSCEPTIBILITY TO CEFEPIME**                                                                                                             
  TF-15166                                 2006       48                                24                                     2       0.25    16    H296P, A215V
  TF-19023                                 2007       \>256                             32                                     4       0.25    32    H296P
  TF-15816                                 2006       \>256                             64                                     8       0.38    128   S287N
  TF-18991                                 2007       96                                32                                     1       0.25    64    S287C, A215V
  TF-25456                                 2010       16                                \>256                                  0.125   0.25    32    A215V
  TF-16290                                 2006       32                                34                                     0.38    0.125   16    A292V
  TF-20098                                 2007       8                                 48                                     0.19    0.5     16    A89T, P194A, A220T, R232C
  **SUSCEPTIBLE CONTROLS**                                                                                                                           
  TF-15829                                 2006       24                                \>256                                  0.125   0.25    64    none
  TOP 10                                   --         0.19                              4                                      0.023   0.19    1     none

CAZ, ceftazidime; FOX, cefoxitin; FEP, cefepime; IMI, imipenem; XNL, ceftiofur.

Discussion {#s4}
==========

In this study, we report the first ESAC producers in animals worldwide. Contrary to humans (Barnaud et al., [@B3]; Mammeri et al., [@B24]), ESACs were exclusively searched and found in the *E. coli* species. This results from the low proportion of animal infections due to other Gram negative bacteria expressing a chromosomal *ampC* gene, such as *S. marcescens*, *E. cloacae, E. aerogenes*, *A. baumanii*, or *P. aeruginosa* (Nordmann and Mammeri, [@B32]). Also, all ESAC-producing *E. coli* were from cattle as a result of our study design, and further investigations are surely needed to explore other animal sectors. The prevalence of ESAC-producing *E. coli* in cattle in France was investigated over a 6-year period of 2005--2010 and estimated at 0.37% (23/6158) in clinical isolates. Of note, this prevalence is similar to that found at a French hospital in the Paris suburb, where six ESAC producers were reported out of 2800 *E. coli* isolates (0.21%) (Mammeri et al., [@B21]). This prevalence is however four times higher than that found at another French hospital, where 41 AmpC-overproducing *E. coli* isolates accounted for 0.16% of all clinical *E. coli* isolates studied, of which only 11 produced ESACs (Cremet et al., [@B11]). However, in that study, inclusive criteria for ESAC producers included a MIC superior or equal to 64 mg/L of ceftazidime, which may have been a factor of underestimation.

Here, ESAC producers were mostly detected in diarrheic calves, which are also known as the main reservoir of ESBL genes in cattle (Madec et al., [@B19], [@B20]; Valat et al., [@B42]). This may reflect the overall high antibiotic pressure with beta-lactams in infections of the enteric tract of young animals. However, a subset of 607 *E. coli* isolates from healthy cattle was also investigated, which revealed an even higher ESAC prevalence compared to diseased ones (5/607, 0.82%). This mirrors the situation in humans where ESAC producers were most likely found in *E. coli* belonging to the less pathogenic phylogroups A or B1 (Mammeri et al., [@B25]; Corvec et al., [@B10]). Moreover, the cattle ESAC-producing *E. coli* isolates predominantly belonged to the CC23, similarly to what has been reported in humans (Cremet et al., [@B11]). Further studies would be needed to understand why this evolution of the chromosomal *ampC* gene of *E. coli* seems restricted to the same genetic lineages in humans and animals despite different antimicrobial pressures and a rather host-specific distribution of the *E. coli* clones.

This study also provides an overview of 23 *ampC* promoter/attenuator sequences in cefoxitin-resistant *E. coli* from cattle. Contrary to humans, reports on mutations in the *ampC* promoter/attenuator regions of *E. coli* from animal sources are scarce (Brinas et al., [@B5]; Guillouzouic et al., [@B15]). The polymorphism at positions −88, −82, −42, −18, −1, +58 found in strong *ampC* promoters (Olsson et al., [@B33]; Guillouzouic et al., [@B15]) was highly conserved in our collection. In particular, this includes the −42 mutation shown to increase *ampC* gene expression (Nelson and Elisha, [@B31]; Caroff et al., [@B7]), and the association of the −42 and −18 changes, which creates two displaced new −35 and −10 boxes with an optimal 17-pb spacer region. The −18 mutation without the −42 mutation was rare (one isolate only) but had already been reported, in particular in *E. coli* isolates which do not over-express their chromosomal AmpC (Brinas et al., [@B4]). Other reported changes were not detected here, such as mutations −32, −11, or +6 (Caroff et al., [@B7]; Corvec et al., [@B9]; Mulvey et al., [@B28]; Tracz et al., [@B40]). However, these mutations might be more frequent in *E. coli* isolates of B2 or D phylogroups, which are not well represented here (Mammeri et al., [@B21]). The deletion of the entire attenuator was not observed either (Tracz et al., [@B39]).

In this study, all relevant amino acid replacements found in the *ampC* gene (namely S287N, S287C, A292V, and H296P) were single substitutions, confirming that cumulating substitutions in the catalytic site is not a preferential evolutionary scheme for AmpCs, contrary to class A beta-lactamases, as previously demonstrated (Le Turnier et al., [@B18]). A new A215V replacement was reported here in four *E. coli* isolates, either as a single or an associated mutation. This mutation, which occurs close to the DAEX motif in the Ω loop, has obviously little if no impact on the cefepime susceptibility. Indeed, in the corresponding native isolates, reduced susceptibility to cefepime may result from decreased permeability and/or oxacillinase production. Also, in the recombinant clones, the wild-type *ampC* gene of the cefepime susceptible control conferred the same MIC to cefepime than the A215V replacement. The main structural alteration found was the S287N replacement, which occurred in the H-9 helix close to the R2 loop. This mirrors the situation in humans where the S287N substitution has been shown to widely contribute to the ESAC phenotype (Mammeri et al., [@B25]). Similarly, other substitutions were also found, such as the S287C mutation, or both the H296P or the A292V mutations inside the R2 loop. Comparison of MICs of cefepime also confirmed that the S287N substitution has greater impact on resistance than the others (Mammeri et al., [@B25]).

Altogether this study is, to our best knowledge, the very first report of ESACs in animals. In humans, those enzymes have likely evolved from wild-type AmpCs by modifications in the vicinity of the R1 or R2 active sites. While the ESACs described here strongly resemble the human ones in both their genetic backgrounds and the responsible mutations, the driving forces for the selection of ESACs in animals are still unknown. In humans, the ESAC phenotype frequently occurs after cefepime therapy. On the contrary, different ESCs are used in animals, whose possible impact needs to be considered. In particular, ceftiofur is an ESC which is widely used in animals, and elevated MICs values to ceftiofur were found here in the recombinant *E. coli* clones. Hence, the use of veterinary cephalosporins in the selection of ESAC producers in animals might be a plausible hypothesis. Of note, most human and animal ESAC *E. coli* reported so far belong to the CC23---a well-adapted *E. coli* clone in the two hosts -, so that the transfer of ESAC producers from humans to animals may have contributed as well. Alternately, this may result from a favorable genetic background of the *ampC* genes in *E. coli* isolates of phylogroup A, irrespective of their human or animal origin (Mammeri AAC 2009). Even though data in humans report similar ranges of ESACs vs. plasmidic AmpCs (Mammeri et al., [@B21]), the true prevalence of ESACs in animals should be further investigated since this emerging mechanism surely contributes to the global burden of resistance to ESCs in animals.
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